Our Mission
PeopleBeatingCancer supports an evidence-based integrative approach to cancer care. For most newly diagnosed patients, FDA-approved therapies form the foundation of treatment, while evidence-based complementary therapies may help reduce side effects and improve survivorship.
Click the orange button to the right to learn more.
Tecentriq® (Atezolizumab) for Cancer: What Patients Need to Know
Tecentriq® (Atezolizumab) for Cancer: What Patients Need to Know. A Complete Guide to Benefits, Side Effects, Integrative Therapies, and Recovery
Tecentriq® (generic name: atezolizumab) is an immunotherapy drug known as an immune checkpoint inhibitor.
Unlike chemotherapy, which directly damages rapidly dividing cells, Tecentriq helps remove one of the biological “brakes” that cancer cells can use to suppress the immune system.
Tecentriq is different from Keytruda (pembrolizumab) and Opdivo (nivolumab) in an important way.
- Keytruda and Opdivo block PD-1
- Tecentriq blocks PD-L1
The goal is similar: allow immune cells—particularly T-cells—to recognize and attack cancer more effectively.
Tecentriq is now used in several cancers, particularly lung cancer, liver cancer, melanoma, a rare soft-tissue sarcoma, and selected patients with muscle-invasive bladder cancer.
The challenge with Tecentriq, as with other checkpoint inhibitors, is that taking the brakes off the immune system can sometimes cause immune cells to attack healthy organs.
These immune-related adverse events (irAEs) can affect the lungs, colon, liver, thyroid, kidneys, skin, endocrine glands and, more rarely, other organs.
That makes Tecentriq fundamentally different from traditional chemotherapy: patients need to understand not only whether the drug can control their cancer, but also how to recognize immune-related side effects early.
Before beginning Tecentriq for cancer, consider discussing:
- Cancer prehabilitation
- Nutrition and gut microbiome health
- Moderate regular exercise
- Adequate protein intake
- Sleep
- Vitamin D testing
- All supplements and medications
- Baseline thyroid, liver and kidney function
- Any history of autoimmune disease or organ transplantation
I am a long-term survivor of an incurable blood cancer called multiple myeloma. My research and experience with evidence-based non-conventional therapies are the reason why I have lived in complete remission from my incurable blood cancer since achieving complete remission in early 1999. I have learned that the best way to manage cancer is to combine the best of conventional and evidence-based non-conventional therapies.
I have learned that therapy-induced side effects can be life-threatening while ruining quality of life. Consider therapies shown to reduce possible side effects.
Scroll down the page and post a question or a comment if there’s anything you’d like to know about breast cancer.
Good luck,
David Emerson
What is Integrative Oncology?
What Is Tecentriq?
| Drug | Generic Name | Drug Class |
|---|---|---|
| Tecentriq | Atezolizumab | PD-L1 immune checkpoint inhibitor |
Cancer cells can sometimes protect themselves from the immune system by exploiting the PD-1/PD-L1 checkpoint pathway.
Normally, this pathway helps keep immune activity under control.
But cancer can use it as a shield.
In simplified terms:
Cancer cell PD-L1 → binds PD-1 on T-cell → T-cell activity is suppressed
Tecentriq binds PD-L1.
Tecentriq → blocks PD-L1 → reduces the inhibitory signal → T-cell remains more capable of attacking cancer
This is why Tecentriq is called a PD-L1 checkpoint inhibitor.
Unlike chemotherapy, Tecentriq does not primarily work by poisoning or directly destroying rapidly dividing cells. It changes the interaction between the cancer and the immune system.
That difference explains both its potential for durable responses and its unusual side-effect profile.
Tecentriq® (Atezolizumab) for Cancer
Which Cancers Is Tecentriq Used to Treat?
As of 2026, FDA-approved Tecentriq indications include selected patients with:
Non-Small Cell Lung Cancer (NSCLC)
Tecentriq can be used in several NSCLC settings, including:
- Adjuvant treatment following surgery and platinum-based chemotherapy for certain stage II-IIIA tumors expressing PD-L1
- First-line treatment of selected metastatic NSCLC with high PD-L1 expression and without EGFR or ALK genomic abnormalities
- Certain metastatic NSCLC combination regimens
- Certain patients whose disease has progressed during or after platinum-containing chemotherapy
Small Cell Lung Cancer
Tecentriq can be combined with carboplatin and etoposide as first-line treatment for extensive-stage small cell lung cancer.
It also has a maintenance indication with lurbinectedin for selected patients with extensive-stage small cell lung cancer whose disease has not progressed following initial treatment.
Hepatocellular Carcinoma
Tecentriq plus bevacizumab (Avastin) is used for selected patients with unresectable or metastatic hepatocellular carcinoma who have not previously received systemic therapy.
Melanoma
Tecentriq can be combined with cobimetinib and vemurafenib for selected patients with BRAF V600 mutation-positive unresectable or metastatic melanoma.
Alveolar Soft Part Sarcoma
Tecentriq is approved for adults and children aged two and older with unresectable or metastatic alveolar soft part sarcoma (ASPS).
Muscle-Invasive Bladder Cancer
An important new indication was added in 2026.
Tecentriq can be used as adjuvant therapy after cystectomy for selected adults with muscle-invasive bladder cancer who have circulating tumor DNA molecular residual disease (ctDNA MRD) detected with an FDA-authorized test.
This is particularly interesting because it illustrates an emerging direction in oncology:
using liquid-biopsy evidence of microscopic residual cancer to help determine who should receive additional treatment after surgery.
Tecentriq® (Atezolizumab) for Cancer
How Effective Is Tecentriq?
There is no single “Tecentriq success rate.”
The benefit varies considerably depending upon:
- Cancer type
- Cancer stage
- PD-L1 expression
- Tumor genetics
- Previous treatments
- Overall health
- Combination therapy
- Tumor burden
- Immune biology
For some patients, immunotherapy can produce responses lasting much longer than would historically have been expected from chemotherapy alone.
Small Cell Lung Cancer
Long-term follow-up of patients receiving atezolizumab plus carboplatin/etoposide in the IMpower133 program reported estimated overall survival rates of approximately:
- 16% at 3 years
- 13% at 4 years
- 12% at 5 years
Five-year survival in extensive-stage small cell lung cancer was historically uncommon, making these long-term responders particularly important.
Hepatocellular Carcinoma
In the IMbrave150 trial, Tecentriq plus bevacizumab improved survival compared with sorafenib.
Updated results reported:
| Treatment | Median Overall Survival |
| Atezolizumab + bevacizumab | 19.2 months |
| Sorafenib | 13.4 months |
Median progression-free survival was also longer with atezolizumab plus bevacizumab.
The important lesson is that Tecentriq does not benefit every patient.
But a subset of patients can experience deep and sometimes durable responses.
Tecentriq® (Atezolizumab) for Cancer
How Is Tecentriq Given?
Tecentriq is generally administered by intravenous infusion.
Common adult dosing schedules include:
- 840 mg every 2 weeks
- 1,200 mg every 3 weeks
- 1,680 mg every 4 weeks
The exact schedule depends upon the cancer, treatment setting, and other drugs being given.
The first infusion is generally administered over approximately 60 minutes.
If tolerated, subsequent infusions may be given over approximately 30 minutes.
Some treatment settings have a defined duration—for example, certain adjuvant treatments may continue for up to one year—while metastatic treatment may continue according to response, tolerability and the treatment protocol.
Common Tecentriq Side Effects
The side effects experienced by an individual patient depend partly upon whether Tecentriq is given alone or in combination with chemotherapy, targeted therapy or bevacizumab.
Common side effects of Tecentriq used alone include:
| Side Effect | Patient Consideration |
| Fatigue/weakness | Very common across immunotherapy |
| Decreased appetite | Monitor weight and nutrition |
| Nausea | Usually manageable but should be reported if persistent |
| Cough | Important because new cough can also signal pneumonitis |
| Shortness of breath | Requires attention because immune pneumonitis must be ruled out |
When Tecentriq is combined with chemotherapy, additional common problems can include:
- Hair loss
- Constipation
- Diarrhea
- Nausea
- Fatigue
- Appetite loss
With Tecentriq plus bevacizumab for liver cancer, common adverse effects include:
- Hypertension
- Fatigue
- Proteinuria
This is an important point:
Not every symptom occurring during Tecentriq treatment is caused by Tecentriq itself.
Combination drugs may have completely different toxicity profiles.
Serious Immune-Related Side Effects
This may be the most important section of this post.
Checkpoint inhibitors can cause the immune system to attack normal tissue.
These reactions can occur during treatment or after treatment has ended and, although many are manageable when detected early, severe immune-mediated reactions can be life-threatening.
| Organ/System | Possible Immune Toxicity | Symptoms Worth Reporting |
| Lungs | Pneumonitis | New cough, chest pain, shortness of breath |
| Colon | Colitis | Persistent diarrhea, blood/mucus in stool, abdominal pain |
| Liver | Hepatitis | Jaundice, nausea, right-sided abdominal pain |
| Thyroid | Hypothyroidism/hyperthyroidism | Fatigue, weight change, temperature intolerance, palpitations |
| Pituitary | Hypophysitis | Headache, severe fatigue, hormonal changes |
| Adrenal glands | Adrenal insufficiency | Weakness, dizziness, nausea, low blood pressure |
| Pancreas/endocrine system | Type 1 diabetes | Excessive thirst, frequent urination, confusion |
| Kidneys | Nephritis | Changes in urination, swelling, abnormal kidney tests |
| Skin | Immune-mediated dermatitis | Rash, blistering, painful skin lesions |
| Heart | Myocarditis | Chest pain, palpitations, shortness of breath |
| Nervous system | Neurologic immune reactions | Weakness, numbness, confusion or unusual neurologic symptoms |
The FDA warns that immune-mediated reactions can occur in any organ system or tissue.
Do not wait until your next infusion to mention a new symptom.
A new cough, diarrhea, unusual fatigue, rash, severe headache or other unexplained symptom may seem minor.
During checkpoint inhibitor therapy, it can sometimes represent the beginning of an immune-related adverse event.
Early recognition can make treatment considerably easier.
How Are Immune-Related Side Effects Treated?
Treatment depends upon severity.
For mild reactions, oncologists may monitor symptoms while continuing treatment.
For more significant reactions, treatment may involve:
- Temporarily withholding Tecentriq
- Corticosteroids
- Hormone replacement for endocrine damage
- Additional immunosuppressive medication when corticosteroids are insufficient
- Permanently discontinuing Tecentriq for certain severe toxicities
- This creates an unusual situation.
Tecentriq activates the immune response against cancer, while corticosteroids may be needed to calm excessive immune activity when healthy organs become targets.
The goal is to control dangerous inflammation without unnecessarily compromising cancer treatment.
Integrative Therapies During Tecentriq
Integrative therapies should support conventional cancer treatment—not replace it.
The strongest evidence generally supports interventions that maintain physical function, nutrition, sleep and quality of life rather than supplements claiming to “boost” the immune system.
1. Exercise ★★★★★
Regular moderate exercise can help reduce:
- Cancer-related fatigue
- Muscle loss
- Physical deconditioning
- Anxiety
- Depression
- Loss of functional capacity
For many cancer survivors, a reasonable long-term goal is approximately 150 minutes of moderate physical activity per week, adjusted for treatment tolerance and medical limitations.
Even short daily walks and light resistance exercise may be useful when patients cannot tolerate conventional workouts.
2. Mediterranean-Style Diet ★★★★★
A Mediterranean-style eating pattern emphasizes:
- Vegetables
- Fruit
- Whole grains
- Beans
- Nuts
- Seeds
- Olive oil
- Fish
- Minimally processed foods
Potential benefits include improved:
- Cardiovascular health
- Metabolic health
- Gut microbiome diversity
- Overall nutritional status
Diet should be viewed as supportive care—not as a replacement for Tecentriq.
3. Adequate Protein ★★★★★
Cancer and cancer treatment can accelerate muscle loss.
Protein supports:
- Muscle maintenance
- Recovery
- Physical activity
- Wound healing
- Overall nutritional status
Protein requirements should be individualized, particularly for patients with kidney or liver disease.
4. Sleep Optimization ★★★★★
Cancer-related fatigue cannot always be solved simply by sleeping more.
However, good sleep remains fundamental to:
- Physical recovery
- Cognitive function
- Mood
- Immune regulation
- Quality of life
Strategies may include:
- Consistent sleep and wake times
- Morning daylight exposure
- Regular daytime physical activity
- Limiting late-night screen exposure
- Cognitive behavioral therapy for insomnia (CBT-I)
5. Vitamin D Optimization ★★★★☆
Vitamin D deficiency is common in cancer patients.
Vitamin D is important for:
- Bone health
- Muscle function
- Immune regulation
Some observational research has explored associations between vitamin D status and immunotherapy outcomes, but vitamin D should not be considered an established treatment for improving Tecentriq response.
A reasonable approach is:
Test → identify deficiency → correct appropriately → retest
rather than automatically taking high-dose vitamin D.
6. Mindfulness / Meditation ★★★★☆
Mindfulness-based interventions can help some cancer patients manage:
- Anxiety
- Depression
- Stress
- Sleep problems
- Quality-of-life challenges
These therapies do not treat the cancer itself but may make the treatment experience easier to manage.
The Gut Microbiome and Tecentriq
This is one of the most interesting emerging areas of immunotherapy research.
The intestinal microbiome interacts extensively with the immune system, and studies of checkpoint inhibitors suggest that gut microbial composition may influence immunotherapy response.
Possible food-first strategies include:
- Eating a variety of plant foods
- Increasing dietary fiber when tolerated
- Vegetables
- Fruits
- Legumes
- Whole grains
- Nuts and seeds
- Fermented foods when appropriate
Another potentially important issue is antibiotic exposure.
Antibiotics are sometimes medically necessary and can be lifesaving. They should never be avoided when needed.
However, unnecessary antibiotic use may disrupt gut microbial diversity, which is one reason cancer patients should discuss antibiotic exposure with their oncology team.
Supplements Requiring Caution During Tecentriq
This area deserves more caution than many cancer websites acknowledge.
Because Tecentriq works by altering immune regulation, supplements marketed as “immune boosters” should not automatically be assumed to be beneficial.
Use particular caution with:
- High-dose antioxidant supplements
- High-dose vitamin E
- High-dose beta-carotene
- Multiple immune-stimulating herbal products
- Large supplement combinations
- Products making claims that they enhance checkpoint inhibitors without clinical evidence
The biological question is not simply:
“Does this supplement strengthen immunity?”
The more relevant question is:
“Could this supplement alter the immune response, interact with treatment, or affect immune-related toxicity?”
Food and supplements are not interchangeable.
A diet rich in fruits and vegetables is not the same thing as taking pharmacologic doses of isolated antioxidants.
Give your oncologist a complete list of every vitamin, supplement, herb and over-the-counter medication you take.
Monitoring During Tecentriq Treatment
Patients receiving Tecentriq should expect regular monitoring.
This commonly includes:
- Liver enzymes
- Kidney function/creatinine
- Thyroid function
- Blood counts when appropriate
- Metabolic testing
- Blood pressure when bevacizumab is used
- Urine protein monitoring when bevacizumab is used
- Imaging to evaluate tumor response
- Assessment for new respiratory, gastrointestinal, skin, neurologic or endocrine symptoms
The FDA specifically recommends evaluating liver enzymes, creatinine, and thyroid function at baseline and periodically during treatment.
But laboratory monitoring alone is not enough.
Patients themselves are part of the monitoring system.
Before Every Tecentriq Infusion, Ask Yourself:
Is anything different from the last time I was here?
For example:
- New cough?
- More shortness of breath?
- New diarrhea?
- New rash?
- Unusual weakness?
- New headache?
- Dizziness?
- Heart palpitations?
- Increased thirst?
- Increased urination?
- Unexplained weight change?
- Severe fatigue that feels different from ordinary cancer fatigue?
Tell your oncology team.
Even symptoms that seem unrelated may matter.
Questions to Ask Your Oncologist Before Tecentriq
- Why are you recommending Tecentriq for my cancer?
- Is Tecentriq FDA-approved for my specific cancer and treatment setting?
- Does my tumor need PD-L1 testing?
- Are there other biomarkers that could affect my treatment choice?
- Will I receive Tecentriq alone or with chemotherapy, bevacizumab or targeted therapy?
- What is the goal of treatment—cure, reducing recurrence risk, long-term disease control or symptom relief?
- How long do you expect me to remain on Tecentriq?
- Which side effects require an immediate phone call?
- What blood tests will you monitor?
- Do I have an autoimmune condition that could increase my risk?
- Could any of my supplements interfere with treatment?
- What happens if I develop an immune-related side effect?
- When would you use corticosteroids?
- Would a severe side effect mean stopping Tecentriq permanently?
- What happens if Tecentriq does not control my cancer?
PeopleBeatingCancer Evidence Rating
| Therapy | Evidence | PBC Recommendation |
| Moderate exercise | ★★★★★ | Strongly recommended when medically appropriate |
| Mediterranean-style diet | ★★★★★ | Strong supportive-care strategy |
| Adequate protein/nutrition | ★★★★★ | Strongly recommended; individualize when necessary |
| Sleep optimization | ★★★★★ | Strongly recommended |
| Mindfulness/meditation | ★★★★☆ | Recommended for stress and symptom management |
| Vitamin D if deficient | ★★★★☆ | Test first; supplement appropriately |
| High-fiber food/gut microbiome support | ★★★★☆ | Promising; food-first approach |
| Routine probiotic supplements | ★★☆☆☆ | Evidence remains uncertain; discuss with oncology team |
| “Immune-boosting” supplements | ★☆☆☆☆ | Insufficient evidence; potential concern during immunotherapy |
| High-dose antioxidant supplementation during active treatment | ★☆☆☆☆ | Avoid routine use without oncology guidance |
How to interpret the PeopleBeatingCancer Evidence Rating
★★★★★ — Strong evidence
Supported by substantial clinical evidence and generally appropriate as supportive cancer care.
★★★★☆ — Good/emerging evidence
Evidence supports potential benefit, although cancer-specific or immunotherapy-specific data may still be developing.
★★★☆☆ — Promising but incomplete evidence
Reasonable biological or clinical evidence exists, but larger controlled trials are needed.
★★☆☆☆ — Limited or conflicting evidence
Potential benefit remains uncertain.
★☆☆☆☆ — Insufficient evidence or reason for caution
Should not be used specifically to improve cancer outcomes without discussion with the oncology team.
Tecentriq vs. Keytruda vs. Opdivo
Patients frequently encounter all three names.
| Immunotherapy | Generic Name | Target |
| Tecentriq | Atezolizumab | PD-L1 |
| Keytruda | Pembrolizumab | PD-1 |
| Opdivo | Nivolumab | PD-1 |
All three interfere with the same general checkpoint pathway, but they bind different components of it.
This means they are not automatically interchangeable.
Their FDA-approved indications, combination regimens, biomarker requirements, and clinical-trial evidence differ.
The appropriate checkpoint inhibitor depends upon the specific cancer and clinical situation.
Tecentriq® (Atezolizumab) for Cancer
Key Takeaways
- Tecentriq (atezolizumab) is a PD-L1 immune checkpoint inhibitor.
- Unlike chemotherapy, it helps restore immune activity against cancer rather than directly killing rapidly dividing cells.
- Tecentriq is used in selected patients with non-small cell lung cancer, small cell lung cancer, hepatocellular carcinoma, melanoma, alveolar soft part sarcoma and muscle-invasive bladder cancer.
- Some patients experience durable responses, but Tecentriq does not work for everyone.
- Immune-related adverse events are fundamentally different from ordinary chemotherapy toxicity.
- The lungs, colon, liver, thyroid, endocrine glands, kidneys, skin and other organs can be affected.
- New or worsening symptoms should be reported promptly rather than waiting for the next oncology appointment.
- Exercise, good nutrition, adequate protein, sleep and stress management have strong evidence for supporting health and quality of life during cancer treatment.
- Gut microbiome research is promising but does not yet justify unproven probiotic or supplement regimens.
- Supplements advertised as “immune boosters” deserve particular caution during checkpoint inhibitor therapy.
- Integrative therapies should complement—not replace—evidence-based cancer treatment.
To Learn More
To Prepare for Tecentriq
- Immunotherapy for Cancer: What Patients Need to Know Before, During, and After Treatment
- Cancer prehabilitation
- Integrative Oncology: Combining Conventional and Natural Cancer Therapies
- Complementary Cancer Therapies: Evidence-based
- Enhancing Your Gut Microbiome
- Vitamin D and Cancer
- Exercise During Cancer Treatment
Tecentriq-Related Side Effects
- Managing Cancer Treatment Side Effects: An Evidence-Based Guide to Prevention, Relief, and Recovery
- Cancer-Related Fatigue
- Immunotherapy Side Effects
- Cancer Treatment and Your Heart
- Diarrhea During Cancer Treatment
- Kidney Damage During Cancer Treatment
- Cancer Financial Toxicity: Costs, Medical Debt, Insurance, Financial Assistance, and Survivorship
Related Immunotherapy Guides
- Immunotherapy for Cancer: What Patients Need to Know Before, During, and After Treatment
- Keytruda® (Pembrolizumab) for Cancer: What Patients Need to Know
- Opdivo (Nivolumab) for Cancer: What Patients Need to Know
- Yervoy (Ipilimumab) for Cancer: What Patients Need to Know
Research
FDA — Tecentriq Prescribing Information
Current indications, dosing, immune-mediated adverse reactions, monitoring and safety information.
FDA — Atezolizumab for Muscle-Invasive Bladder Cancer
In May 2026, the FDA approved atezolizumab as adjuvant treatment after cystectomy for adults with muscle-invasive bladder cancer who have detectable ctDNA molecular residual disease.
IMpower133 — Extensive-Stage Small Cell Lung Cancer
Long-term follow-up demonstrates a small but important population of long-term survivors following first-line atezolizumab plus carboplatin/etoposide.
IMbrave150 — Hepatocellular Carcinoma
Atezolizumab plus bevacizumab improved overall and progression-free survival compared with sorafenib in unresectable hepatocellular carcinoma.
Tecentriq® (Atezolizumab) for Cancer
Medical disclaimer: This article is educational and is not a substitute for individualized medical advice. Immunotherapy can cause serious or life-threatening immune-mediated adverse events. Patients receiving Tecentriq should discuss new symptoms, supplements and treatment decisions with their oncology team.
Tecentriq® (Atezolizumab) for Cancer Tecentriq® (Atezolizumab) for Cancer Tecentriq® (Atezolizumab) for Cancer Tecentriq® (Atezolizumab) for Cancer